Consilient Health Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Consilient Health Ltd.
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
The US green light for Alkindi is a big step for the UK biotech in its bid to become a world-leading specialty endocrinology business.
- Group Purchasing
- Home Infusion
- Generic Drugs
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.